ARTICLE | Company News
Epttco Ltd., Vion, AstraZeneca deal
March 26, 2001 8:00 AM UTC
AZN will not exercise its option to finance development of TAPET-CPG2, a VION bacterial vector combined with Epttco’s CPG2 prodrug converting enzyme. VION said AZN’s decision resulted from less than e...